TAMBOCOR
LOE ApproachingNDAORALTABLET
Approved
Oct 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAMBOCOR (flecainide acetate) is an oral antiarrhythmic agent approved in 1985 for the treatment of cardiac arrhythmias. The exact mechanism of action and specific indications are not publicly detailed in available data, but it represents a legacy small-molecule cardiovascular therapeutic. This product is currently approaching loss of exclusivity.
LOE Approaching
Product is in pre-LOE phase with moderate competitive pressure (30/100), indicating team focus likely shifting toward lifecycle extension, generic preparation, or cost-optimization strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAMBOCOR offers limited career upside given its LOE-approaching status and zero linked job openings. Career value lies in gaining experience in lifecycle management, generic defense, and portfolio transition planning rather than growth-stage innovation.
Brand ManagerCommercial Operations
Worked on TAMBOCOR at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.